Enzymatic degradation of Dynasan 114 SLN - Effect of surfactants and particle size

Journal of Nanoparticle Research

Volumn 4, Issue 1-2, 2002, Pages 121-129

  Olbrich, Carsten ^a   Kayser, Oliver ^a   Müller, Rainer Helmut ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Colloidal drug carrier system; Enzymatic degradation; Lipase; SLN (solid lipid nanoparticles)

Indexed keywords

EID: 0036374026     PISSN: 13880764     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020159331420     Document Type: Article

References (28)

1. Bunjes H., K. Westesen & M.H.J. Koch, 1996. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 129, 159-173.
2. Blunk T., D.F. Hochstrasser, J.-C. Sanchez, B.W. Müller & R.H. Müller, 1993. Colloidal Carriers for Intravenous Drug Targeting: Plasma Protein Adsorption Patterns on Surface-Modified Latex Particles Evaluated by Two-dimensional Polyacrylamide Gel Electrophoresis, Electrophoresis. 14, 1382-1387.
3. Brokman H.L., 2000. Kinetic behavior of the pancreatic lipase-colipase-lipid system, Biochimie 82, 987-995.
4. Grizzi I., H. Garreau, S. Li & M. Vert, 1995. Hydrolytic degradation of devices based on poly(DL-lactic acid) - size-dependence. Biomaterials 16, 305-311.
5. Holmberg K., M. Nyden, L.-T. Lee, M. Malmsten & J.K. Brajesh Jha, 2000. Interactions between a lipase and charged surfactants - a comparison between bulk and interfaces. Adv. Colloids Int. Sci. 88, 223-241.
6. Jenning V., M. Schäfer-Körting & S. Gohla, 2000. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Controlled Release 15, 115-126.
7. Kazzaz J., J. Neidleman, M. Singh, G. Ott & D.T. O'Hagan, 2000. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1, J. Controlled Release 67, 347-156.
8. Moghimi S.M., 1999. Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration: applications in cancer drug delivery and imaging. Biochim. Biophys. Acta 18, 399-403.
9. Müller R.H., C. Lherm, P. Jaffray & P. Couvreur, 1988. Toxicity of cyanoacrylate particles in 1929 fibroblast cell cultures - relation between toxicity and in vitro characterization parameters. Arch. Pharm. 321, 681ff.
10. Müller R.H., 1991. Colloidal carriers for controlled drug delivery and targeting - modification, characterization and in vivo distribution. Wissenschaftliche Verlagsgesellschaft Stuttgart. CRC Press, Boca Raton, 379S.
11. Müller R.H., W. Mehnert, J.S. Lucks, C. Schwarz, A. zur Mühlen, H. Weyhers, C. Freitas & D. Rühl, 1995. Solid lipid nanoparticles (SLN) - an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41, 62-69.
12. Müller R.H., J.S. Lucks, 1996. Arzneistoffträger aus festen Lipidteilchen. Feste Lipidnanosphären (SLN). European Patent No. 0605497.
13. Müller R.H., N. Grubhofer & C. Olbrich, 1999. Stabilitäts-. Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort. German Patent Application No. 199 23 256.3.
14. Müller R.H. & C. Olbrich, 1999. Solid lipid nanoparticles (SLN): Phagocytic uptake, in vitro cytotoxity and in vivo biodegradation. Ist Communication. Pharm. Ind. 61, 462-467.
15. Müller R.H., K. Mäder & S. Gohla, 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177.
16. Olbrich C., W. Mehnert & R.H. Müller, 1997. Effect of surfactant and lipid composition on the in vitro degradation time of solid lipid nanoparticles (SLN). Intern. Symp. Control. Rel. Bioact. Mater. 24, 921-922.
17. Olbrich C., W. Mehnert, R.H. Müller, 1998. In vitro degradation properties of Solid Lipid Nanoparticles SLN™. 2nd World Meeting APGI/APV, Paris, pp. 577-578.
18. Olbrieh C., W. Mehnert & R.H. Müller, 1998. Development of an in vitro degradation assay for solid lipid nanoparticles. 2nd World Meeting APGI/APV, Paris, pp. 627-628
19. Olbrich C., R.H. Müller, 1999. Enzymatic degradation of SLN Effect of surfactant and surfactant mixtures. Int. J. Pharm. 180, 31-39.
20. Olbrich C., O. Kayser, R.H. Müller, N. Grubhofer, 2000. Solid lipid nanoparticles (SLN) as vaccine adjuvant - study in sheep with a mycoplasma bovis antigen and stability testing. Intern. Symp. Control. Rel. Bioact. Mater. 27, 8110.
21. Olbrich C., N. Schöler, K. Tabatt, R.H. Müller & O. Kayser. Cytotoxicity of anionic and cationic solid lipid nanoparticles (SLN) on RAW 264.7 cells. ATLA (in preparation).
22. Olbrich C., R.H. Müller & O. Kayser. Enzymatic degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of storage time and rate of crystallinity. Int. J. Pharm. (accepted).
23. Penkler L., R.H. Müller, S.A. Runge & V. Ravelli, 1999. Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften. Erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung (Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties. Improved physical quality and greater stability and method for producing said formulation). PCT-application PCT/EP99/02892. Priority Date: 30 April 1998. International submission date: 29 April 1999.
24. Schöler N., C. Olbrich, K. Tabatt, N. Conrad, R.H. Müller, H. Hahn & O. Liesenfeld, 2001. Cytotoxicity of SLN on peritoneal mouse macrophages. Int. J. Pharm. 221, 57-61.
25. Singh M., M. Briones, G. Ott & D. O'Hagan, 2000. Cationic microparticles: A potent delivery system for DNA vaccines. 1. Proc. Natl. Acad. Sci. USA 97, 811-816.
26. Wannerberger K., M. Wahlgren & T. Arnebrant, 1996. Adsorption from lipase-surfactant solutions onto methylated silica surfaces. Colloids Surf. B 6, 27-36.
27. Winkler F.K., A. D'Arcy & W. Hunziker, 1990. Structure of human pancreatic lipase. Nature 343, 771-774.
28. zur Muhlen A., C. Schwarz & W. Mehnert, 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism. Eur. J. Pharm. Biopharm. 45, 149-155.